Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at William Blair.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an "overweight" rating on the stock.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil [Yahoo! Finance]
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... [Yahoo! Finance]